DSEY vs PROG

Diversey Holdings Ltd.

Diversey Holdings, Ltd., through its subsidiaries, provides infection prevention and cleaning solutions in Europe, North America, Latin America, the Asia Pacific, the Middle East, and Africa. It operates through two segments, Institutional, and Food and Beverage. The company manufactures, markets, and sells infection prevention and personal care products; floor and building care chemicals; kitchen and mechanical ware wash chemicals, and machines; dosing and dispensing equipment; and floor care machines to healthcare, education, food service, retail and grocery, hospitality, and building service contractor industries. It also provides a range of engineering, consulting, and training services related to productivity management, water and energy management, and risk management. In addition, the company offers chemical products; engineering and equipment solutions; training; and knowledge-based services, as well as water treatment services to brewing, beverage, dairy, processed foods, pharmaceutical, and agriculture industries. Diversey Holdings, Ltd. was founded in 1923 and is headquartered in Northampton, United Kingdom.

Progenity Inc.

Progenity, Inc., a biotechnology company, provides develops and commercializes molecular testing products in the United States. It offers Innatal, a noninvasive prenatal screening test offered to women early in pregnancy to screen for chromosome abnormalities, such as down syndrome, trisomy 18, trisomy 13, and sex chromosome disorders through the analysis of cell-free DNA; Preparent that screens for carrier status of hereditary diseases prior to or early in pregnancy; and Riscover, a hereditary cancer screen that analyzes 31 genes associated with inherited risk of 12 types of cancers, including the BRCA1/2 genes for hereditary breast, ovarian, colorectal, endometrial, pancreatic, and other cancer syndromes, as well as for the five genes associated with Lynch syndrome. The company also provides Resura, a noninvasive prenatal test for families at risk for rare single gene disorders; and Preecludia, a preeclampsia rule-out test. In addition, it offers anatomic and molecular pathology tests, and COVID-19 PCR testing services, as well as test products that includes chromosomal microarray for pregnancy loss, which evaluates the genetic cause of miscarriage; maternal serum screening for chromosomal disorders; and preimplantation genetic testing for use with artificial reproductive technologies. Further, the company develops therapeutic solutions for gastrointestinal-related disorders, such as PGN-001, PGN-300, PGN-600, and PGN-OB2. It also owns and operates laboratory. Progenity, Inc. was formerly known as Ascendant MDX, Inc. and changed its name to Progenity, Inc. in November 2013. The company was founded in 2010 and is headquartered in San Diego, California.